Caas Capital Management LP 2seventy Bio, Inc. Transaction History

Caas Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$9.21 - $14.98 $132,467 - $215,457	14,383 New	14,383 $146,000
Q3 2022 Nov 14, 2022	SELL	$12.56 - $17.54 $5.91 Million - $8.26 Million	-470,891 Reduced 67.35%	228,245 $3.32 Million
Q2 2022 Aug 15, 2022	BUY	$10.55 - $18.81 $5.84 Million - $10.4 Million	553,171 Added 378.98%	699,136 $9.23 Million
Q1 2022 May 13, 2022	SELL	$11.67 - $26.72 $655,305 - $1.5 Million	-56,153 Reduced 27.78%	145,965 $2.49 Million
Q4 2021 Feb 14, 2022	BUY	$13.77 - $42.56 $2.78 Million - $8.6 Million	202,118 New	202,118 $5.18 Million

126

45.6M

122K

19.8K

Ticker TSVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,873,600
Market Cap $113M
Description
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...

Get notified when there are updates to the investment portfolio of Caas Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Caas Capital Management LP with notifications on news.